These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35404285)

  • 1. Spillover: The Approval of New Medications for Alzheimer's Disease Dementia Will Impact Biomarker Disclosure Among Asymptomatic Research Participants.
    Mozersky J; Roberts JS; Rumbaugh M; Chhatwal J; Wijsman E; Galasko D; Blacker D;
    J Alzheimers Dis; 2022; 90(3):1035-1043. PubMed ID: 35404285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Informing Disclosure: Efficacy of a Brief Educational Intervention on Research Participants' Knowledge about Alzheimer's Disease Biomarkers.
    Ketchum FB; Erickson CM; Basche KE; Chin NA; Rosario HL; Johnson SC; Clark LR
    J Alzheimers Dis; 2023; 96(2):515-522. PubMed ID: 37807783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
    Jansen WJ; Janssen O; Tijms BM; Vos SJB; Ossenkoppele R; Visser PJ; ; Aarsland D; Alcolea D; Altomare D; von Arnim C; Baiardi S; Baldeiras I; Barthel H; Bateman RJ; Van Berckel B; Binette AP; Blennow K; Boada M; Boecker H; Bottlaender M; den Braber A; Brooks DJ; Van Buchem MA; Camus V; Carill JM; Cerman J; Chen K; Chételat G; Chipi E; Cohen AD; Daniels A; Delarue M; Didic M; Drzezga A; Dubois B; Eckerström M; Ekblad LL; Engelborghs S; Epelbaum S; Fagan AM; Fan Y; Fladby T; Fleisher AS; Van der Flier WM; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Frings L; Frisoni GB; Fröhlich L; Gabryelewicz T; Gertz HJ; Gill KD; Gkatzima O; Gómez-Tortosa E; Grimmer T; Guedj E; Habeck CG; Hampel H; Handels R; Hansson O; Hausner L; Hellwig S; Heneka MT; Herukka SK; Hildebrandt H; Hodges J; Hort J; Huang CC; Iriondo AJ; Itoh Y; Ivanoiu A; Jagust WJ; Jessen F; Johannsen P; Johnson KA; Kandimalla R; Kapaki EN; Kern S; Kilander L; Klimkowicz-Mrowiec A; Klunk WE; Koglin N; Kornhuber J; Kramberger MG; Kuo HC; Van Laere K; Landau SM; Landeau B; Lee DY; de Leon M; Leyton CE; Lin KJ; Lleó A; Löwenmark M; Madsen K; Maier W; Marcusson J; Marquié M; Martinez-Lage P; Maserejian N; Mattsson N; de Mendonça A; Meyer PT; Miller BL; Minatani S; Mintun MA; Mok VCT; Molinuevo JL; Morbelli SD; Morris JC; Mroczko B; Na DL; Newberg A; Nobili F; Nordberg A; Olde Rikkert MGM; de Oliveira CR; Olivieri P; Orellana A; Paraskevas G; Parchi P; Pardini M; Parnetti L; Peters O; Poirier J; Popp J; Prabhakar S; Rabinovici GD; Ramakers IH; Rami L; Reiman EM; Rinne JO; Rodrigue KM; Rodríguez-Rodriguez E; Roe CM; Rosa-Neto P; Rosen HJ; Rot U; Rowe CC; Rüther E; Ruiz A; Sabri O; Sakhardande J; Sánchez-Juan P; Sando SB; Santana I; Sarazin M; Scheltens P; Schröder J; Selnes P; Seo SW; Silva D; Skoog I; Snyder PJ; Soininen H; Sollberger M; Sperling RA; Spiru L; Stern Y; Stomrud E; Takeda A; Teichmann M; Teunissen CE; Thompson LI; Tomassen J; Tsolaki M; Vandenberghe R; Verbeek MM; Verhey FRJ; Villemagne V; Villeneuve S; Vogelgsang J; Waldemar G; Wallin A; Wallin ÅK; Wiltfang J; Wolk DA; Yen TC; Zboch M; Zetterberg H
    JAMA Neurol; 2022 Mar; 79(3):228-243. PubMed ID: 35099509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.
    van der Schaar J; Visser LNC; Bouwman FH; Ket JCF; Scheltens P; Bredenoord AL; van der Flier WM
    Alzheimers Res Ther; 2022 Feb; 14(1):31. PubMed ID: 35144684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.
    Long JM; Coble DW; Xiong C; Schindler SE; Perrin RJ; Gordon BA; Benzinger TLS; Grant E; Fagan AM; Harari O; Cruchaga C; Holtzman DM; Morris JC
    Brain; 2022 Dec; 145(12):4506-4518. PubMed ID: 35867858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evolution of the diagnostic frontiers of Alzheimer's disease and new therapeutic possibilities].
    Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(11. Vyp. 2):38-44. PubMed ID: 36412155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker disclosure protocols in prodromal Alzheimer's disease clinical trials.
    Rahman-Filipiak A; Bolton C; Grill JD; Rostamzadeh A; Chin N; Heidebrink J; Getz S; Fowler NR; Rosen A; Lingler J; Wijsman E; Clark L;
    Alzheimers Dement; 2023 Sep; 19(9):4270-4275. PubMed ID: 37450489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the Ethical Issues of a Biomarker-Based Diagnoses in the Early Stage of Alzheimer's Disease.
    Vanderschaeghe G; Dierickx K; Vandenberghe R
    J Bioeth Inq; 2018 Jun; 15(2):219-230. PubMed ID: 29532386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.
    Ketchum FB; Chin NA; Grill J; Gleason CE; Erickson C; Clark LR; Paulsen JS; Kind AJH
    Alzheimers Dement; 2022 Oct; 18(10):1969-1979. PubMed ID: 35213786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time.
    Shepherd-Banigan ME; Ford CB; Smith VA; Belanger E; Wetle TT; Plassman BL; Burke JR; DePasquale N; O'Brien EC; Sorenson C; Van Houtven CH
    J Alzheimers Dis; 2022; 90(2):775-782. PubMed ID: 36189596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
    Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease.
    Bateman RJ; Cummings J; Schobel S; Salloway S; Vellas B; Boada M; Black SE; Blennow K; Fontoura P; Klein G; Assunção SS; Smith J; Doody RS
    Alzheimers Res Ther; 2022 Nov; 14(1):178. PubMed ID: 36447240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of sharing Alzheimer's disease biomarkers with individuals without dementia: A systematic review and meta-analysis of empirical data.
    van der Schaar J; Visser LNC; Ket JCF; Groot C; Pijnenburg YAL; Scheltens P; Bredenoord AL; van den Hoven MA; van der Flier WM
    Alzheimers Dement; 2023 Dec; 19(12):5773-5794. PubMed ID: 37496313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants.
    Erickson CM; Karlawish J; Grill JD; Harkins K; Landau SM; Rivera-Mindt MG; Okonkwo O; Petersen RC; Aisen PS; Weiner MW; Largent EA
    J Prev Alzheimers Dis; 2024; 11(2):294-302. PubMed ID: 38374735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-disclosure distress among racial and ethnic groups in a preclinical AD trial.
    Ritchie M; Salazar CR; Gillen DL; Grill JD
    Alzheimers Dement; 2024 Apr; 20(4):2508-2515. PubMed ID: 38329007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the personal utility of Alzheimer's disease-related biomarker testing in the research context.
    Bunnik EM; Richard E; Milne R; Schermer MHN
    J Med Ethics; 2018 Dec; 44(12):830-834. PubMed ID: 30154216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes.
    Jack CR; Wiste HJ; Botha H; Weigand SD; Therneau TM; Knopman DS; Graff-Radford J; Jones DT; Ferman TJ; Boeve BF; Kantarci K; Lowe VJ; Vemuri P; Mielke MM; Fields JA; Machulda MM; Schwarz CG; Senjem ML; Gunter JL; Petersen RC
    Brain; 2019 Oct; 142(10):3230-3242. PubMed ID: 31501889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.